



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*January 11, 2005*

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/529,643

FILING DATE: *December 15, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/42007*

Certified By



Jon W Dudas

Under Secretary  
of Commerce for Intellectual Property  
and Acting Director of the  
United States Patent and Trademark Office

**BEST AVAILABLE COPY**

DEC. 11. 2003 1:38PM

16138 U.S. PTO

**Provisional Application Cover Sheet**Address to:  
Washington, DC 20231Express Mail #:  
EU666379445US

This is a request for filing a PROVISIONAL APPLICATION under 37 C.F.R. § 1.53(b)(2).

Docket Number: Q3325		Type a plus sign (+) inside this box		+
Investor(s)/Applicant(s)				
Last Name	First Name	Middle Initial	Residence (City and either State or Foreign Country)	
Diamond Gozalia	Scott Dhaval		Bala Cynwyd, PA Philadelphia, PA	
Title of the Invention (280 Characters Maximum)				
Methods and Devices for Running Reactions on a Target Plate for MALDI Mass Spectrometry				
Correspondence Address				
University of Pennsylvania Center For Technology Transfer 3160 Chestnut Street Suite 200				
City: Philadelphia		State: Pennsylvania	Zip Code: 19104 - 6283	Country: US
Enclosed Application Parts (check all that apply)				
[X] Specification Number of pages: 22 [ ] Small Entity Statement				
[ ] Drawing(s) Number of sheets: [ ] Other (specify)				
Method of Payment (check one)				
[ ] Our Check No. _____ is enclosed to cover the Provisional filing fees. A duplicate copy of this sheet is enclosed.			Provisional Filing Fee Amount (\$)	\$ 80.00
[X] The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 13-2489. A duplicate copy of this sheet is enclosed.				
[ ] Payment by credit card. Form PTO-2028 is attached.				

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

[ ] No

[ ] Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

Signature: Scott L. DiamondDate: 12-12-03

Typed or Printed Name: Scott Diamond

[ ] Additional inventors are being named on separately numbered sheets attached hereto.

**PROVISIONAL APPLICATION FILING ONLY**22154 U.S. PTO  
60/529643

121503

**PROVISIONAL APPLICATION SUBMISSION TO USPTO – CONTENTS PAGE**

Penn Docket Number : Q3325  
First-named Inventor : Diamond  
Submission Date : 12/15/03  
Prepared by : Matt Thomas

**CONTENTS LISTED IN ORDER :**

<u>Page Nos.</u>	<u>Descriptor</u>
1	This Page
2-3	Abstract, "Methods . . . Spectrometry"
4-5	List of Claims
6	Lists of Applications and Potential License Partners
7-20	Figures
21-22	"Amino Acid Calculation Results" Charts

Total Number of Pages : 22

**TITLE:** Methods and Devices for running reactions  
on a target plate for MALDI mass spectrometry

**INVENTORS:** Scott L. Diamond and Dhaval Gosalia  
Institute for Medicine and Engineering  
University of Pennsylvania

**INVENTION DATE:** Friday, September 19, 2003

**DISCLOSURE DATE:** Monday, September 21, 2003

The method allows the ability to run individual nanoliter to microliter volume liquid reactions at positions on a mass spectrometry (MS) target plate ("target"). The target is a metal surface that is flat or has wells or has coatings or grooves to maintain sample position. Additional constituents are added to each reaction by various liquid handling protocols to initiate reactions. Finally, the constituents and products of each reaction volume are prepared by vacuum drying and aerosol deposition of MALDI matrix followed by mass spectrometry without the need to remove the sample from the MS target for various typical manipulations (desalting, extraction, digestion, MALDI matrix addition and formation). The technology has application towards reaction optimization, high throughput drug discovery, high throughput drug selectivity profiling or toxicity testing. A range from 100 to 1000 reaction samples per square centimeter of target can be achieved. Reaction volumes can range from 1 nanoliter to 2000 nanoliters.

#### **NOVEL FEATURES**

- 1) Method for running biological reactions on a MS target followed by MALDI mass spectrometry analysis of the samples on the target without the need to remove the sample from the target for desalting, solvent exchange, digestion, matrix addition, matrix formation.
- 2) Ability to conduct high throughput drug testing on a MALDI MS target.
- 3) Method and machine to create outstanding quality matrix for MALDI mass spectrometry.
- 4) Ability to run 100 to 1000 samples per square centimeter of MALDI target.
- 5) Allows unique opportunities to conduct liquid chromatography (LC) MALDI MS for improved sample throughput.

## **BACKGROUND**

Proteomics and high throughput screening (HTS) are activities that involve the analysis of hundreds to millions of samples. In drug screening, reactions are run in well-plates to produce optical signals (fluorescence, luminescence) indicating that a hit was identified. The search for "label free" drug screening could rely on matrix assisted laser desorption ionization (MALDI) mass spectrometry (MS) which has excellent throughput. However, the reaction constituents would have to be prepared for MS which involves desalting the sample and adding matrix to each sample and then placing each sample on the target. These liquid handling steps are time consuming and expensive and limit the use of MALDI for HTS. The need to conduct HTS on a MALDI target would meet industry demands for label-free HTS with high capacity (10K to 100K screens per day). The disclosed technology allows HTS reactions to be run on a MALDI plate followed by MALDI MS analysis with a detection limit of 1 femtomole of a peptide in 50 nanoliters of sample. This disclosure also allows the power of contact pin printers to load MALDI plates at up to 1000 spots per square centimeter. MALDI matrix can be applied with such high quality that ultrasmall liquid samples can be used while still generating outstanding crystals for the MALDI process to allow ultrasensitive detections.

In proteomics, complex biological samples are separated by 2D electrophoresis and gel plugs are desalted and digested through a throughput-limiting process requiring expensive liquid handling. These steps limit the throughput of proteomics facilities. To avoid the problems of 2D electrophoresis, labs have used liquid chromatography and capillary electrophoresis. The described technology allows the effluent of LC or CE to be placed on the plate for subsequent coating with MALDI matrix.

### **Competing Technology**

We are not aware of prior examples of running biological reactions on a MALDI plate.

We are not aware of prior examples of creating a MALDI matrix by aerosol deposition.

We are aware of no device on the market for aerosol deposition of MALDI matrix onto a target.

**What is CLAIMED:**

- 1) A metal target on which individual liquid or solid reactants are placed at unique positions on a MS target by liquid handling (pin printing, piezo printing, positive displacement liquid handling etc.) at volumes ranging from 1 nanoliter to 2000 nanoliters.
- 2) A target on which subsequent reagents (1 picoliter to 2000 nanoliters) are delivered to each position on the MS target as described in Claim 1 and individual chemical reactions are allowed to proceed.
- 3) Where the reaction of Claim 2 liquid constituents of the reaction (solvents) are removed by air drying or vacuum drying to leave a defined position of deposition of caked materials.
- 4) Where MALDI matrix ("matrix") is coated onto the dry target by spray deposition without the need for micropositioning of matrix delivery to each individual sample and whereby the samples do not cross contaminate each other due to the discontinuous nature of an aerosol and the spacing between the samples.
- 5) Where the MALDI matrix of Claim 4 is a thin film achieved by aerosol deposition to a coating of less than 50 microns by delivery of no more than 10 microliters of MALDI matrix solution delivered to more than 5 sq. cm. of target surface.
- 6) Where the MALDI matrix of Claim 4 contains volatile solvents such as water and acetonitrile and a supersaturated concentration of MALDI matrix.
- 7) Where the dry MALDI matrix coating is humidified to achieve outstanding crystals for MALDI mass spectrometry with concomitant mixing of the constituents of the reaction sample into the MALDI matrix.
- 8) Where the MALDI matrix formed in Claim 7 allows detection of peptides and modified peptides at concentrations in the range of 1 to 50 femtomole of peptide in a 1 to 100 nanoliter sample.
- 9) Where mobile ions (salt) diffuse from the reaction into surrounding matrix formed by the Method of Claim 7 thereby reducing there concentration by radial diffusion away from the original sample position.
- 10) Where feature size of the biological reaction ranges of Claim 1 and Claim 2 are from 200 to 1000 microns in diameter by use of contact printing or positive-displacement liquid handling.
- 11) Whereby the processed "target" is subjected to MALDI MS for analysis of reactants and products formed by reaction at each position by negative or positive mode and by linear or reflectron mode.
- 12) Where the components of Claim 1 are enzymes, peptides, proteins, DNA, RNA, nucleotides, amino acids, and substrates, catalysts, salts, buffers, and cofactors.
- 13) Where the components of Claim 2 are enzymes, peptides, proteins, DNA, RNA, nucleotides, amino acids, and substrates, catalysts, salts, buffers, and cofactors.
- 14) Where the reactions formed in Claim 2 are at high densities of ranging form 10 to 1000 reactions per square centimeter of the target.

- 15) Where the reactions formed in Claim 2 are useful for detecting drug like activity in a high throughput drug discovery process.
- 16) Where the reactions formed in Claim 2 are useful for determining the interaction of a drug with many other proteins such as kinases, P450 enzymes, phosphatases, proteases, etc.
- 17) A device and its operation for spraying MALDI Matrix on a target where the target is moved at 0.5 to 2 inches per sec and the matrix solution is aerosolized with an ultrasonic nozzle (0.5 to 1 W) or spray nozzle with carrier gas at a flowrate of 0.5 to 2 microliters per minute. Several coatings can be achieved for highly controlled film thickness of the MALDI Matrix.

#### **RELATED TO PRIOR PATENT APPLICATIONS BY DIAMOND**

- 17) Where the subcomponents of each reaction (enzymes, catalysts, buffers) are positioned on a flat target in 1 to 100 nanoliter droplets of a nonvolatile liquid such as glycerol by the use of contact printing.
- 18) Where the subcomponents of each reaction of Claim 1 are stored on the surface of the target in a controlled environment and can be shipped to alternate locations for use at later times.
- 19) Where the subcomponents of Claim 2 to be added to the reaction are delivered by aerosol deposition.
- 20) Where the target comes pre-prepared with numerous enzymes and prepared reaction components for distribution to other users who activate the target and use the methods of the described technology to run the target in their MS machine.


**Applications:**

- 1) On-target digestion of proteins for MALDI
- 2) On-target triggering of bioreactions by addition of a limiting reagent.
- 3) Highthroughput proteomics
- 4) Highthroughput reaction optimization

**Potential Licence Partners (nonexclusive)**

- 1) Reaction Biology Corporation
- 2) ABI
- 3) Waters
- 4) Perkin Elmer
- 5) Bruker Daltronics
- 6) various proteomics and Mass spectrometry companies.
- 7) Genomic Solutions

**Figure 1**



## FIGURE 2

A series of Mass Spectrum for control fibrinogen and on-target treated fibrinogen activated with thrombin (10 U/ml) in 50 nanoliter reactions.

Concentrations were:	18 mg/ml	52.8 micromolar
	9 mg/ml	26.4 micromolar
	4.5 mg/ml	13.2 micromolar
	3 mg/ml	8.8 micromolar
	1.5 mg/ml	4.4 micromolar
	0.75 mg/ml	2.2 micromolar

### Spectrum Peaks

Fibrinogen (no reaction)	1264.19 m/z (contamination)
Fibrinogen + thrombin	1539.64 m/z Fibrinopeptide A (calculated 1536.6)
	1555.74 m/z Fibrinopeptide B (calculated 1569.60)

### Reaction

Fibrinogen + thrombin  $\rightarrow$  fibrin monomer + 2 Fibrinopeptide A + 2 Fibrinopeptide B




## EXAMPLES

Fibrinogen 18mg/ml



Fibrinopeptide A = 1536  
Fibrinopeptide B = 1568




Laser power  
Same for all  
Conc. = 1800

Matrix sprayed  
Sinapic acid  
Linear positive  
mode





Fibrinogen 18mg/ml  
Control





Fibrinogen 9mg/ml

Fibrinogen 9mg/ml  
Control



Voyager Spec #1 (BP = 155.6, 169.7)

Mass (m/z)

% Intensity

155.05

126.4

128.4

137.04

146.23



169.6

180.3



190.3


210.6

250.0





Fibrinogen 4.5mg/ml  
Control










Fibrinogen 3mg/ml





Fibrinogen 3mg/ml  
Control






# Fibrinogen 1.5mg/ml





Fibrinogen 1.5mg/ml  
Control



# Fibrinogen 0.75mg/ml



Fibrinogen 0.75mg/ml  
Control



# Amino Acid Calculation Results

Amino Acid Sequence				
ADSGEGDFLAEGGGVR				
Fibrinopeptide A				
N-Terminal Group: Hydrogen		Mono Isotopic Mass: 1535.68516		Sequence Length: 16
C-Terminal Group: Free Acid		Average Mass: 1536.5755		
Symbols	Name	Mono Mass	Average Mass	Count
Ala A	Alanine	71.03711	71.07880	2
Arg R	Arginine	156.10111	156.1876	1
Asn N	Asparagine	114.04293	114.1039	
Asp D	Aspartic Acid	115.02694	115.0886	2
Cys C	Cysteine	103.00919	103.1448	
Glu E	Glutamic Acid	129.04259	129.1155	2
Gln Q	Glutamine	128.05858	128.1308	
Gly G	Glycine	57.02146	57.0520	5
His H	Histidine	137.05891	137.1412	
Ile I	Isoleucine	113.08406	113.1595	
Leu L	Leucine	113.08406	113.1595	1
Lys K	Lysine	128.09496	128.1742	
Met M	Methionine	131.04049	131.1986	
Phe F	Phenylalanine	147.06841	147.1766	1
Pro P	Proline	97.05276	97.1167	
Ser S	Serine	87.03203	87.0782	1
Thr T	Threonine	101.04768	101.1051	
Trp W	Tryptophan	186.07931	186.2133	
Tyr Y	Tyrosine	163.06333	163.1760	
Val V	Valine	99.06841	99.1326	1

Please direct problems/questions to: Michael MacCoss

# Amino Acid Calculation Results

Amino Acid Sequence				
QGVNDNEEGFFSAR Fibrinopeptide B				
N-Terminal Group: Hydrogen		Mono Isotopic Mass: 1568.68552		Sequence Length: 14
C-Terminal Group: Free Acid		Average Mass: 1569.6078		
Symbols	Name	Mono Mass	Average Mass	Count
Ala A	Alanine	71.03711	71.07880	1
Arg R	Arginine	156.10111	156.1876	1
Asn N	Asparagine	114.04293	114.1039	2
Asp D	Aspartic Acid	115.02694	115.0886	1
Cys C	Cysteine	103.00919	103.1448	
Glu E	Glutamic Acid	129.04259	129.1155	2
Gln Q	Glutamine	128.05858	128.1308	1
Gly G	Glycine	57.02146	57.0520	2
His H	Histidine	137.05891	137.1412	
Ile I	Isoleucine	113.08406	113.1595	
Leu L	Leucine	113.08406	113.1595	
Lys K	Lysine	128.09496	128.1742	
Met M	Methionine	131.04049	131.1986	
Phe F	Phenylalanine	147.06841	147.1766	2
Pro P	Proline	97.05276	97.1167	
Ser S	Serine	87.03203	87.0782	1
Thr T	Threonine	101.04768	101.1051	
Trp W	Tryptophan	186.07931	186.2133	
Tyr Y	Tyrosine	163.06333	163.1760	
Val V	Valine	99.06841	99.1326	1

Please direct problems/questions to: Michael MacCoss

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/042007

International filing date: 15 December 2004 (15.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/529,643  
Filing date: 15 December 2003 (15.12.2003)

Date of receipt at the International Bureau: 24 January 2005 (24.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**